These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 37772552

  • 1. Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12D Inhibitor, in Colorectal Cancer Treatment.
    Kataoka M, Kitazawa M, Nakamura S, Koyama M, Yamamoto Y, Miyazaki S, Hondo N, Tanaka H, Soejima Y.
    Anticancer Res; 2023 Oct; 43(10):4341-4348. PubMed ID: 37772552
    [Abstract] [Full Text] [Related]

  • 2. Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer.
    Feng J, Hu Z, Xia X, Liu X, Lian Z, Wang H, Wang L, Wang C, Zhang X, Pang X.
    Oncogene; 2023 May; 42(20):1620-1633. PubMed ID: 37020035
    [Abstract] [Full Text] [Related]

  • 3. KRAS inhibitors: going noncovalent.
    Drosten M, Barbacid M.
    Mol Oncol; 2022 Dec; 16(22):3911-3915. PubMed ID: 36383067
    [Abstract] [Full Text] [Related]

  • 4. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
    Lee HW, Son E, Lee K, Lee Y, Kim Y, Lee JC, Lim Y, Hur M, Kim D, Nam DH.
    Int J Mol Sci; 2019 Nov 24; 20(23):. PubMed ID: 31771279
    [Abstract] [Full Text] [Related]

  • 5. MEK inhibitor and anti-EGFR antibody overcome sotorasib resistance signals and enhance its antitumor effect in colorectal cancer cells.
    Hondo N, Kitazawa M, Koyama M, Nakamura S, Tokumaru S, Miyazaki S, Kataoka M, Seharada K, Soejima Y.
    Cancer Lett; 2023 Jul 28; 567():216264. PubMed ID: 37336286
    [Abstract] [Full Text] [Related]

  • 6. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC, Tsai TY, Yadav VK, Deng L, Huang CC, Tzeng YM, Yeh CT, Chen MY.
    Int J Mol Sci; 2021 Jul 14; 22(14):. PubMed ID: 34299137
    [Abstract] [Full Text] [Related]

  • 7. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL.
    Oncogene; 2011 Feb 03; 30(5):561-74. PubMed ID: 20956938
    [Abstract] [Full Text] [Related]

  • 8. Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutation.
    Tajiknia V, Pinho-Schwermann M, Srinivasan PR, Hernandez Borrero L, Zhang L, Huntington KE, El-Deiry WS.
    Am J Cancer Res; 2024 Feb 03; 14(9):4523-4536. PubMed ID: 39417197
    [Abstract] [Full Text] [Related]

  • 9. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor.
    Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD, Laguer J, Medwid J, Vanderpool D, Lifset E, Trinh D, Hoffman N, Wang X, David Lawson J, Gunn RJ, Smith CR, Thomas NC, Martinson M, Bergstrom A, Sullivan F, Bouhana K, Winski S, He L, Fernandez-Banet J, Pavlicek A, Haling JR, Rahbaek L, Marx MA, Olson P, Christensen JG.
    Nat Med; 2022 Oct 03; 28(10):2171-2182. PubMed ID: 36216931
    [Abstract] [Full Text] [Related]

  • 10. Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRASG12D inhibitors for cancer therapy.
    Issahaku AR, Mukelabai N, Agoni C, Rudrapal M, Aldosari SM, Almalki SG, Khan J.
    Sci Rep; 2022 Oct 22; 12(1):17796. PubMed ID: 36273239
    [Abstract] [Full Text] [Related]

  • 11. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
    Chen P, Li X, Zhang R, Liu S, Xiang Y, Zhang M, Chen X, Pan T, Yan L, Feng J, Duan T, Wang D, Chen B, Jin T, Wang W, Chen L, Huang X, Zhang W, Sun Y, Li G, Kong L, Chen X, Li Y, Yang Z, Zhang Q, Zhuo L, Sui X, Xie T.
    Theranostics; 2020 Oct 22; 10(11):5107-5119. PubMed ID: 32308771
    [Abstract] [Full Text] [Related]

  • 12. A systems mechanism for KRAS mutant allele-specific responses to targeted therapy.
    McFall T, Diedrich JK, Mengistu M, Littlechild SL, Paskvan KV, Sisk-Hackworth L, Moresco JJ, Shaw AS, Stites EC.
    Sci Signal; 2019 Sep 24; 12(600):. PubMed ID: 31551296
    [Abstract] [Full Text] [Related]

  • 13. Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography.
    Achmad A, Hanaoka H, Yoshioka H, Yamamoto S, Tominaga H, Araki T, Ohshima Y, Oriuchi N, Endo K.
    Cancer Sci; 2012 Mar 24; 103(3):600-5. PubMed ID: 22126621
    [Abstract] [Full Text] [Related]

  • 14. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
    Lee SK, Cho YH, Cha PH, Yoon JS, Ro EJ, Jeong WJ, Park J, Kim H, Il Kim T, Min DS, Han G, Choi KY.
    Exp Mol Med; 2018 Nov 20; 50(11):1-12. PubMed ID: 30459318
    [Abstract] [Full Text] [Related]

  • 15. Honokiol enhances the sensitivity of cetuximab in KRASG13D mutant colorectal cancer through destroying SNX3-retromer complex.
    Zhu Q, Zhang R, Gu X, Zhao Z, Gao Q, Chen M, Wu Q, Xie T, Sui X.
    Theranostics; 2024 Nov 20; 14(14):5443-5460. PubMed ID: 39310106
    [Abstract] [Full Text] [Related]

  • 16. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
    Vitiello PP, Cardone C, Martini G, Ciardiello D, Belli V, Matrone N, Barra G, Napolitano S, Della Corte C, Turano M, Furia M, Troiani T, Morgillo F, De Vita F, Ciardiello F, Martinelli E.
    J Exp Clin Cancer Res; 2019 Jan 28; 38(1):41. PubMed ID: 30691487
    [Abstract] [Full Text] [Related]

  • 17. Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways.
    Liu YF, Feng ZQ, Chu TH, Yi B, Liu J, Yu H, Xue J, Wang YJ, Zhang CZ.
    Phytomedicine; 2024 Apr 28; 126():155462. PubMed ID: 38394734
    [Abstract] [Full Text] [Related]

  • 18. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J, Lee I, Han B, Park JO, Jang J, Park C, Kang WK.
    J Natl Cancer Inst; 2011 Apr 20; 103(8):674-88. PubMed ID: 21398618
    [Abstract] [Full Text] [Related]

  • 19. Synergistic Approach of Antibody-Photosensitizer Conjugate Independent of KRAS-Mutation and Its Downstream Blockade Pathway in Colorectal Cancer.
    Ahn M, Lee T, Kim KS, Lee S, Na K.
    Adv Healthc Mater; 2023 Dec 20; 12(31):e2302374. PubMed ID: 37722358
    [Abstract] [Full Text] [Related]

  • 20. Pathways and mechanism of MRTX1133 binding to KRAS G12D elucidated by molecular dynamics simulations and Markov state models.
    Tu G, Gong Y, Yao X, Liu Q, Xue W, Zhang R.
    Int J Biol Macromol; 2024 Aug 20; 274(Pt 2):133374. PubMed ID: 38925182
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.